American Indian adults have some of the highest alcohol abstinence rates compared to the overall US population. Despite this, many American Indian people are more likely to concurrently use alcohol and illicit drugs and are less likely to participate and remain in outpatient treatment for alcohol and other drug use compared to the general US population. There is limited knowledge about effective interventions targeting alcohol and drug co-addiction among American Indian adults. Contingency management is a behavioral intervention designed to increase drug abstinence by offering monetary incentives in exchange for drug and alcohol negative urine samples. We aim to evaluate and describe a culturally tailored contingency management intervention to increase alcohol and other drug abstinence among American Indian adults residing in a Northern Plains reservation.
Methods
This 2 × 2 factorial, randomized controlled trial currently includes 114 American Indian adults with alcohol and/or drug dependence who are seeking treatment. Participants were randomized into one of four groups that received (1) contingency management for alcohol, (2) contingency management for other drug, (3) contingency management for both substances, or (4) no contingency management for either substance. We present descriptive, baseline data to characterize the sample and describe the modified contingency management approach that is specific to the community wherein this trial was being conducted.
Results
The sample is 49.1% male, with an average age of 35.8 years (standard deviation = 10.4 years). At baseline, 43.0% of the sample tested positive for ethyl glucuronide, 50.9% of participants self-reported methamphetamine as their most used drug, 36.8% self-reported cannabis, and 12.3% self-reported prescription opiates as their most used drug. Among randomized participants, 47.4% tested positive for cannabis, 28.1% tested positive for methamphetamine, 16.7% tested positive for amphetamines, and 2.1% tested positive for opiates.
Conclusion
This is the first study to examine a culturally tailored contingency management intervention targeting co-addiction of two substances among American Indian adults. By establishing a tribal–university partnership to adapt, implement, and evaluate contingency management, we will increase the literature on evidence-based addiction treatments and research, while improving trust for addiction interventions among American Indian communities through ongoing collaboration. Moreover, results have implications for the use of contingency management as an intervention for co-addiction in any population.
GoneJTrimbleJ.American Indian and Alaska Native mental health: diverse perspectives on enduring disparities. Annu Rev Clin Psychol2012; 8: 131–160.
2.
SpicerPBealsJCroyCet al. The prevalence of DSM-III-R alcohol dependence in two American Indian populations. Alcohol Clin Exp Res2003; 27: 1785–1797.
3.
U.S. Department of Health and Human Services. Results from the 2013 National Survey on Drug Use and Health: summary of national findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014.
4.
CunninghamJKSolomonTAMuramotoML.Alcohol use among Native Americans compared to whites: examining the veracity of the “Native American elevated alcohol consumption” belief. Drug Alcohol Depend2016; 160: 65–75.
5.
National Institutes of Health. Alcohol use and alcohol use disorders in the United States: main findings from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism, 2006.
6.
U.S. Department of Health and Human Services. Trends in Indian health. 2014 ed. Rockville, MD: Division of Program Statistics, Office of Public Health Support, Indian Health Service, U.S. Department of Health and Human Services, 2014.
7.
DuranE.Healing the soul wound: counseling with American Indian and other Native peoples. New York: Teachers College Press, 2006.
8.
DuranEDuranB.Native American postcolonial psychology. Albany, NY: State University of New York Press, 1995.
NaimiTSCobbNBoydDet al. Alcohol-attributable deaths and years of potential life lost among American Indians and Alaska Natives—United States, 2001–2005. MMWR Morb Mortal Wkly Rep2008; 57: 938–941.
11.
MitchellCMBealsJNovinsDKet al. Drug use among two American Indian populations: prevalence of lifetime use and DSM-IV substance use disorders. Drug Alcohol Depend2003; 69: 29–41.
12.
BealsJNovinsDKSpicerPet al. Help seeking for substance use problems in two American Indian reservation populations. Psychiatr Serv2006; 57: 512–520.
13.
BealsJSpicerPMitchellCMet al. Racial disparities in alcohol use: comparison of 2 American Indian reservation populations with national data. Am J Public Health2003; 93: 1683–1685.
14.
MidanikLTTamTWWeisnerC.Concurrent and simultaneous drug and alcohol use: results of the 2000 National Alcohol Survey. Drug Alcohol Depend2007; 90: 72–80.
15.
Center for Behavioral Health Statistics Quality. Key substance use and mental health indicators in the United States: results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH Series H-51). Rockville, MD: Substance Abuse and Mental Health Services Administration, 2016.
16.
Substance Abuse Mental Health Services Administration. The NSDUH report: substance use among American Indian or Alaska Native adults. Rockville, MD: Office of Applied Studies, 2010.
17.
FeldsteinSWVennerKLMayPA. American Indian/Alaska Native alcohol-related incarceration and treatment. Am Indian Alaska Native Ment Health Res2006; 13: 1–22.
18.
CallaghanRC.Risk factors associated with dropout and readmission among First Nations individuals admitted to an inpatient alcohol and drug detoxification program. CMAJ2003; 169: 23–27.
19.
GreenfieldBLVennerKL.Review of substance use disorder treatment research in Indian country: future directions to strive toward health equity. Am J Drug Alcohol Abuse2012; 38: 483–492.
20.
O’MalleySSRobinRWLevensonALet al. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska Natives and non-Natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res2008; 32: 1271–1283.
21.
WoodallWGDelaneyHDKunitzSJet al. A randomized trial of a DWI intervention program for first offenders: intervention outcomes and interactions with antisocial personality disorder among a primarily American-Indian sample. Alcohol Clin Exp Res2007; 31: 974–987.
22.
GoneJAlcantaraC.Identifying effective mental health interventions for American Indians and Alaska Natives: a review of the literature. Cultur Divers Ethnic Minor Psychol2007; 13: 356–363.
McDonellMGNepomJRLeicklyEet al. A culturally-tailored behavioral intervention trial for alcohol use disorders in three American Indian communities: rationale, design, and methods. Contemp Clinical Trials2016; 47: 93–100.
25.
BigelowGESilvermanKE.Theoretical and empirical foundations of contingency management treatments for drug abuse. In: HigginsSTSilvermanKE (eds) Motivating behavior change among illicit-drug abusers: research on contingency management interventions. Washington, DC: American Psychological Association, 1999, pp. 15–31.
26.
StangerCBudneyAJ.Contingency management approaches for adolescent substance use disorders. Child Adolesc Psychiatr Clin N Am2010; 19: 547–562.
27.
HigginsSTPetryNM.Contingency management. Incentives for sobriety. Alcohol Res Health1999; 23: 122–127.
28.
MurphySMMcDonellMGMcPhersonSet al. An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness. Drug Alcohol Depend2015; 153: 293–299.
29.
OlmsteadTAPetryNM.The cost-effectiveness of prize-based and voucher-based contingency management in a population of cocaine- or opioid-dependent outpatients. Drug Alcohol Depend2009; 102: 108–115.
30.
OlmsteadTASindelarJLEastonCJet al. The cost-effectiveness of four treatments for marijuana dependence. Addiction2007; 102: 1443–1453.
31.
OlmsteadTASindelarJLPetryNM.Clinic variation in the cost-effectiveness of contingency management. Am J Addict2007; 16: 457–460.
32.
OlmsteadTASindelarJLPetryNM.Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug Alcohol Depend2007; 87: 175–182.
33.
BudneyAJStangerCTilfordJMet al. Computer-assisted behavioral therapy and contingency management for cannabis use disorder. Psychol Addict Behav2015; 29: 501–511.
34.
KurtiANDavisDRednerRet al. A review of the literature on remote monitoring technology in incentive-based interventions for health-related behavior change. Transl Issues Psychol Sci2016; 2: 128–152.
35.
StitzerMLBigelowGELiebsonI.Reinforcement of drug abstinence: a behavioral approach to drug abuse treatment. NIDA Res Monogr1979; 25: 68–90.
36.
HigginsSTBudneyAJBickelWKet al. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry1994; 51: 568–576.
37.
StitzerMLRandCSBigelowGEet al. Contingent payment procedures for smoking reduction and cessation. J Appl Behav Anal1986; 19: 197–202.
38.
HigginsSTStitzerMLBigelowGEet al. Contingent methadone delivery: effects on illicit-opiate use. Drug Alcohol Depend1986; 17: 311–322.
39.
RoblesEStitzerMLStrainECet al. Voucher-based reinforcement of opiate abstinence during methadone detoxification. Drug Alcohol Depend2002; 65: 179–189.
40.
BudneyAJHigginsSTRadonovichKJet al. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol2000; 68: 1051–1061.
41.
KaddenRMLittMDKabela-CormierEet al. Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav2007; 32: 1220–1236.
42.
MillerPM.A behavioral intervention program for chronic public drunkenness offenders. Arch Gen Psychiatry1975; 32: 915–918.
43.
HigginsSTSilvermanKE.Motivating behavior change among illicit-drug abusers: research on contingency management interventions. Washington, DC: American Psychological Association, 1999.
44.
RollJM.Contingency management: an evidence-based component of methamphetamine use disorder treatments. Addiction2007; 102: 114–120.
45.
DutraLStathopoulouGBasdenSLet al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry2008; 165: 179–187.
46.
PrendergastMPodusDFinneyJet al. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction2006; 101: 1546–1560.
47.
LussierJPHeilSHMongeonJAet al. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction2006; 101: 192–203.
48.
PetryNMPeirceJMStitzerMLet al. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry2005; 62: 1148–1156.
49.
PeirceJMPetryNMStitzerMLet al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry2006; 63: 201–208.
50.
HenggelerSWChapmanJERowlandMDet al. Statewide adoption and initial implementation of contingency management for substance-abusing adolescents. J Consult Clin Psychol2008; 76: 556–567.
51.
PillingSStrangJGeradaC.Psychosocial interventions and opioid detoxification for drug misuse: summary of NICE guidance. BMJ2007; 335: 203–205.
52.
HelanderABöttcherMFehrCet al. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcoholism2009; 44: 55–61.
53.
WurstFMMetzgerJ.The ethanol conjugate ethyl glucuronide is a useful marker of recent alcohol consumption. Alcoholism Clin Exp Res2002; 26: 1114–1119.
54.
LittenRZBradleyAMMossHB.Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res2010; 34: 955–967.
55.
HelmusTCSaulesKKSchoenerEPet al. Reinforcement of counseling attendance and alcohol abstinence in a community-based dual-diagnosis treatment program: a feasibility study. Psychol Addict Behav2003; 17: 249–251.
56.
WurstFMKempterCMetzgerJet al. Ethyl glucuronide: a marker of recent alcohol consumption with clinical and forensic implications. Alcohol2000; 20: 111–116.
57.
WurstFMSeidlSLadewigDet al. Ethyl glucuronide: on the time course of excretion in urine during detoxification. Addict Biol2002; 7: 427–434.
58.
WurstFMSkipperGEWeinmannW.Ethyl glucuronide—the direct ethanol metabolite on the threshold from science to routine use. Addiction2003; 98(Suppl. 2): 51–161.
59.
WurstFMTabakoffBAllingCet al. World Health Organization/International Society for Biomedical Research on Alcoholism study on state and trait markers of alcohol use and dependence: back to the future. Alcohol Clin Exp Res2005; 29: 1268–1275.
60.
WurstFMVogelRJachauKet al. Ethyl glucuronide discloses recent covert alcohol use not detected by standard testing in forensic psychiatric inpatients. Alcohol Clin Exp Res2003; 27: 471–476.
61.
SkipperGEWeinmannWThieraufAet al. Ethyl glucuronide: a biomarker to identify alcohol use by health professionals recovering from substance use disorders. Alcohol Alcoholism2004; 39: 445–449.
62.
KipMJSpiesCDNeumannTet al. The usefulness of direct ethanol metabolites in assessing alcohol intake in nonintoxicated male patients in an emergency room setting. Alcohol Clin Exp Res2008; 32: 1284–1291.
63.
SheehanDLecrubierYSheehanHet al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry1998; 59(Suppl. 20): 22–33, quiz 34–57.
64.
KostenTOlivetoAFeingoldAet al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend2003; 70: 315–325.
65.
OlivetoAPolingJSevarinoKAet al. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug Alcohol Depend2005; 79: 157–165.
66.
HarrisPATaylorRThielkeRet al. Research Electronic Data Capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform2009; 42: 377–381.
67.
RollJMHigginsST.A within-subject comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. Drug Alcohol Depend2000; 58: 103–109.
68.
RollJMHigginsSTBadgerGJ.An experimental comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. J Appl Behav Anal1996; 29: 495–505.
69.
McDonellMGLeicklyEMcPhersonSet al. A randomized controlled trial of ethyl glucuronide-based contingency management for outpatients with co-occurring alcohol use disorders and serious mental illness. Am J Psychiatry2017; 174: 370–377.
70.
RollJMChudzynskiJCameronJMet al. Duration effects in contingency management treatment of methamphetamine disorders. Addict Behav2013; 38: 2455–2462.
71.
McDonellMGSrebnikDAngeloFet al. Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness. Am J Psychiatry2013; 170: 94–101.
OrrMFLederhos SmithCFinlayMet al. Pilot investigation: randomized-controlled analog trial for alcohol and tobacco smoking co-addiction using contingency management. Behav Pharmacol2018; 29: 462–468.
74.
RiesRKDyckDGShortRet al. Outcomes of managing disability benefits among patients with substance dependence and severe mental illness. Psychiatr Serv2004; 55: 445–447.
75.
PetryNMMartinBCooneyJLet al. Give them prizes and they will come: contingency management for treatment of alcohol dependence. J Consult Clin Psychol2000; 68: 250–257.
76.
McDonellMGSkaliskyJLeicklyEet al. Using ethyl glucuronide in urine to detect light and heavy drinking in alcohol dependent outpatients. Drug Alcohol Depend2015; 157: 184–187.
77.
CariseDWicksKMcLellanAet al. Addiction Severity Index 5th edition—North Dakota State adaptation for use with Native Americans. Philadelphia, PA: Treatment Research Institute, University of Pennsylvania, 1998.
78.
SobellLCSobellMB.Alcohol Timeline FollowBack. In: Rush JA, Pincus HA and Task Force for the Handbook of Psychiatric Measures (eds) Handbook of psychiatric measures. Washington, DC: American Psychiatric Association, 2000, pp. 477–479.
79.
BarryDWeinstockJPetryNM.Ethnic differences in HIV risk behaviors among methadone-maintained women receiving contingency management for cocaine use disorders. Drug Alcohol Depend2008; 98: 144–153.
80.
DarkeSHallWHeatherNet al. The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. AIDS1991; 5: 181–185.
81.
WareJJrKosinskiMKellerSD.A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care1996; 34: 220–233.
82.
QuandtSAGrahamCNBellRAet al. Ethnic disparities in health-related quality of life among older rural adults with diabetes. Ethn Dis2007; 17: 471–476.
83.
HigginsSTDelaneyDDBudneyAJet al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry1991; 148: 1218–1224.
